Alkem Labs Promoter to Sell 0.7% Stake in Block Deals

Yesterday, on August 21, it was reported that the promoter of Alkem Laboratories Ltd plans to sell a 0.7% stake in the company through block deals which involves offloading 8.5 lakh shares at a price of Rs.5,616 each. This price is set at around 4% discount to the current market price of Rs.5,780 per share. 

Company Performance

Alkem Laboratories has recently announced an impressive financial performance. For Q1FY25, the company’s profit saw a rise of nearly 90%, reaching Rs.545.16 crore, up from Rs.286.73 crore in the same period last year. Revenue for this quarter was reported at Rs.3,031.82 crore, compared to Rs.2,967.72 crore the previous year. The company’s EBITDA amounted to Rs.608.6 crore, resulting in a EBITDA margin of 20.1%, up significantly from 13.1% last year. This represents a 56.4% increase in EBITDA.

Sales Breakdown

The domestic market played a crucial role in driving Alkem’s growth. Domestic sales totaled Rs.2,022.3 crore, with a year-over-year increase of 6.4%. This growth has elevated domestic sales to account for 67.6% of the company’s total sales, an increase from 65.2% in the previous year. Conversely, international sales amounted to Rs.967.7 crore, showing a 4.6% decline from the previous year.

Regulatory & Market Updates

In the US, Alkem Laboratories made huge strides, including the launch of one new product and obtaining three approvals from the US FDA, one of which was a tentative approval. Additionally, the company successfully addressed a US FDA Form 483 issue at its Baddi facility. CEO Vikas Gupta talked about the company’s plans to maintain high standards of quality and regulatory compliance.

Conclusion: To wrap up, the promoter’s decision to sell a 0.7% stake at a 3% discount is likely just them cashing in a bit after a strong quarter. With profits soaring and the company in a good place, it’s probably a way to balance their holdings without shaking things up too much.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.